Grigoriadis Anita, Mackay Alan, Reis-Filho Jorge S, Steele Dawn, Iseli Christian, Stevenson Brian J, Jongeneel C Victor, Valgeirsson Haukur, Fenwick Kerry, Iravani Marjan, Leao Maria, Simpson Andrew J G, Strausberg Robert L, Jat Parmjit S, Ashworth Alan, Neville A Munro, O'Hare Michael J
Ludwig Institute for Cancer Research/University College London Breast Cancer Laboratory, 91 Riding House Street, London, W1W 7BS, UK.
Breast Cancer Res. 2006;8(5):R56. doi: 10.1186/bcr1604.
Diverse microarray and sequencing technologies have been widely used to characterise the molecular changes in malignant epithelial cells in breast cancers. Such gene expression studies to identify markers and targets in tumour cells are, however, compromised by the cellular heterogeneity of solid breast tumours and by the lack of appropriate counterparts representing normal breast epithelial cells.
Malignant neoplastic epithelial cells from primary breast cancers and luminal and myoepithelial cells isolated from normal human breast tissue were isolated by immunomagnetic separation methods. Pools of RNA from highly enriched preparations of these cell types were subjected to expression profiling using massively parallel signature sequencing (MPSS) and four different genome wide microarray platforms. Functional related transcripts of the differential tumour epithelial transcriptome were used for gene set enrichment analysis to identify enrichment of luminal and myoepithelial type genes. Clinical pathological validation of a small number of genes was performed on tissue microarrays.
MPSS identified 6,553 differentially expressed genes between the pool of normal luminal cells and that of primary tumours substantially enriched for epithelial cells, of which 98% were represented and 60% were confirmed by microarray profiling. Significant expression level changes between these two samples detected only by microarray technology were shown by 4,149 transcripts, resulting in a combined differential tumour epithelial transcriptome of 8,051 genes. Microarray gene signatures identified a comprehensive list of 907 and 955 transcripts whose expression differed between luminal epithelial cells and myoepithelial cells, respectively. Functional annotation and gene set enrichment analysis highlighted a group of genes related to skeletal development that were associated with the myoepithelial/basal cells and upregulated in the tumour sample. One of the most highly overexpressed genes in this category, that encoding periostin, was analysed immunohistochemically on breast cancer tissue microarrays and its expression in neoplastic cells correlated with poor outcome in a cohort of poor prognosis estrogen receptor-positive tumours.
Using highly enriched cell populations in combination with multiplatform gene expression profiling studies, a comprehensive analysis of molecular changes between the normal and malignant breast tissue was established. This study provides a basis for the identification of novel and potentially important targets for diagnosis, prognosis and therapy in breast cancer.
多种微阵列和测序技术已被广泛用于表征乳腺癌中恶性上皮细胞的分子变化。然而,此类旨在识别肿瘤细胞中标志物和靶点的基因表达研究,受到实体乳腺肿瘤细胞异质性以及缺乏代表正常乳腺上皮细胞的合适对照的影响。
通过免疫磁珠分离法从原发性乳腺癌中分离出恶性肿瘤上皮细胞,并从正常人乳腺组织中分离出管腔细胞和肌上皮细胞。对这些高度富集的细胞类型制备物的RNA池进行大规模平行签名测序(MPSS)和四种不同的全基因组微阵列平台的表达谱分析。差异肿瘤上皮转录组中功能相关的转录本用于基因集富集分析,以确定管腔和肌上皮类型基因的富集情况。在组织微阵列上对少数基因进行临床病理验证。
MPSS鉴定出正常管腔细胞池与大量富集上皮细胞的原发性肿瘤池之间有6553个差异表达基因,其中98%在微阵列分析中得到体现,60%得到确认。仅通过微阵列技术检测到这两个样本之间有4149个转录本存在显著表达水平变化,从而形成了一个包含8051个基因的综合差异肿瘤上皮转录组。微阵列基因特征分别鉴定出907个和955个转录本的综合列表,其在管腔上皮细胞和肌上皮细胞中的表达存在差异。功能注释和基因集富集分析突出了一组与骨骼发育相关的基因,这些基因与肌上皮/基底细胞相关,并在肿瘤样本中上调。该类别中表达最高的基因之一,即编码骨膜蛋白的基因,在乳腺癌组织微阵列上进行了免疫组织化学分析,其在肿瘤细胞中的表达与一组预后不良的雌激素受体阳性肿瘤的不良预后相关。
通过将高度富集的细胞群体与多平台基因表达谱研究相结合,建立了对正常和恶性乳腺组织之间分子变化的全面分析。本研究为识别乳腺癌诊断、预后和治疗的新的潜在重要靶点提供了基础。